Bioxytran

Bioxytran FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Bioxytran (BIXT) as of Oct 10, 2026 is 25.88 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 3.55 % — a change of 629.88% (higher).

FCF Conversion

25.88 %

YoY

629.88%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Bioxytran is 2025 25.88 % . FCF Conversion Rate (FCF/EBITDA) of Bioxytran was 2024 3.55 % . It decreases by 629.88% higher compared to the previous year.

The Bioxytran FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
62.72 USD
Jan 1, 2019
23.19 USD
Jan 1, 2020
44.71 USD
Jan 1, 2021
43.02 USD
Jan 1, 2022
74.23 USD
Jan 1, 2023
18.33 USD
Jan 1, 2024
3.55 USD
Jan 1, 2025
25.88 USD
The Bioxytran FCF Conversion history
YEARFCF ConversionYoY
25.88 %+629.88%
3.55 %-80.65%
18.33 %-75.31%
74.23 %+72.57%
43.02 %-3.78%
44.71 %+92.76%
23.19 %-63.02%
62.72 %-45,482.49%
-0.14 %-102.27%
6.08 %+4,632.04%
0.13 %-89.38%
1.21 %—
Access this data via the Eulerpool API

Bioxytran Stock analysis

What does Bioxytran do? Bioxytran Inc. is a US-based company specialized in the development of medical therapies based on the use of oxygen transport molecules. The company's patented platform technology focuses on the development of new innovative therapies for treating central nervous system disorders, cardiovascular diseases, and cancer treatment. The company was founded in 2014 by a group of scientists and entrepreneurs aiming to create a transformative medical product that improves oxygen transport in the body and enables the treatment of severe diseases. Bioxytran's platform is based on the use of perfluorocarbon compounds (PFCs) that have a strong affinity for oxygen and can bind and transport it in the blood. The company's business model is centered on the development and commercialization of new therapies to treat diseases such as stroke, heart attack, cancer, and even COVID-19. By improving oxygen transport in the body, Bioxytran aims to enhance the effectiveness of medical treatments and create new therapeutic possibilities. The company's focus areas include stroke treatment, where they have developed a technology that allows direct oxygen transport to the affected brain tissue, minimizing neural damage and enabling faster recovery. They have also developed a new type of heart attack treatment that aims to improve blood flow and eliminate oxygen deficiency in the heart, as well as another therapy option for patients suffering from acute heart attacks. In the field of cancer treatment, Bioxytran has a promising therapy in the pipeline based on PFCs that can selectively target cancer cells, potentially making chemotherapy more effective and patient-friendly. Overall, Bioxytran's goal is to develop medical therapies that have the potential to revolutionize the treatment of severe diseases. They offer a range of products and approaches that have the potential to improve the lives of many patients. In summary, Bioxytran Inc. is an emerging company in the field of medical therapies, driven by innovation and technological expertise. Their focus on developing high-potential products that improve oxygen transport in the body facilitates the treatment of severe diseases. With their various divisions and products, Bioxytran is able to address a broad spectrum of medical needs. Bioxytran is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioxytran stock

FCF Conversion Rate (FCF/EBITDA) of Bioxytran is 25.88 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Bioxytran changed from 3.55 % to 25.88 %, representing a 629.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Bioxytran since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Bioxytran with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Bioxytran

All Key Metrics — Bioxytran